Healthcare Review: ANTH, PSDV, VRSEF, CPRX, BCLI, SUPN, AMRN Making Moves Print E-mail
By Staff and Wire Reports   
Thursday, 19 July 2012 13:33
icon_MarketReportUPU.S. stocks extended gains on Thursday despite the fact that U.S. jobless claims jumped +34,000 to 386,000 last week. Several healthcare stocks are making notable moves at mid day.
Anthera Pharmaceuticals Inc (NASDAQ:ANTH) shares plunged 14.29% to $1.14 after the company announced the pricing of an underwritten public offering of 33 million shares of its common stock, offered at a price of $1.00 per share. The Company estimates that the gross proceeds from the offering, before deducting underwriting discounts and commissions and other estimated offering expenses payable by Anthera, will be $33 million. The offering is expected to close on or about July 24, 2012, subject to customary closing conditions.

SubscriberOnlyContentpSivida Corp. (NASDAQ:PSDV) stock soared 34.58% to $2.88 in the early hour after the company announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application to treat posterior uveitis with pSivida's injectable sustained-release micro-insert. pSivida is now permitted to move directly to two Phase III trials to treat patients with posterior uveitis. These trials would be in addition to the investigator-sponsored trial studying the same device for posterior uveitis announced last month.

Verisante Technology, Inc. (TSX VENTURE:VRS) (OTCQX:VRSEF) (FRANKFURT:V3T) shares are trading over 11.74% higher as the firm prepares their commercial launch of the revolutionary skin cancer detection technology, Verisante Aura(TM), which was recently awarded Popular Science Magazine's "Best of What's New Award" for 2011.

Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) stock climbed 8.33% to $1.04. On July 12, 2012, the company announced that it expects to report top-line results from its CPP-109 (vigabatrin) Phase II(b) trial around the end of September 2012 versus the previous guidance of early in the first quarter of 2013.

BrainStorm Cell Therapeutics Inc. (OTCBB: BCLI) shares shot over 10% higher in early trading. Volume and interest in the stock has been increasing since the Israeli company was featured in various print and televised news reports featuring a compassionate use case in which the first scientifically documented reversal of Amyotrophic lateral sclerosis (or ALS aka Lou Gehrig's Disease) was observed. Speculators are taking positions in the stock ahead of key clinical data which is set to be to be released and could transform the firm's pipeline status.

Supernus Pharmaceuticals Inc (NASDAQ:SUPN) shares climbed 8.74% to $15.88. On July 13, 2012, the company announced on June 26 that it received a tentative approval letter from the Food & Drug Administration for Trokendi XR(TM). The letter states that the FDA completed its review of the Trokendi XR NDA and that no additional clinical trials are required. The letter also states that final approval may not be made effective by the FDA until the period of exclusivity protection associated with safety information regarding a specific pediatric population expires.

Amarin Corporation plc (ADR) (NASDAQ:AMRN) shares gained 5.32% to $15.43. On July 12, 2012, the shares of the company had its "buy" rating restated by analysts at MKM Partners. Separately, analysts at Jefferies Group reiterated a "buy" rating on shares of Amarin Co. plc in a research note to investors on Wednesday, June 27th. They now have a $26.00 price target on the stock, up previously from $24.00.




"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 

Newsletter